At 5.2% CAGR, the Asia Pacific DVT Preventive Pump Market is projected to be worth US$ 107.81 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific DVT preventive pump market was valued at US$ 79.61 million in 2022 and is expected to reach US$ 107.81 million by 2028, registering a CAGR of 5.2% from 2022 to 2028. Mounting cases of cardiac disorders and stroke and significant surge in geriatric population and expanding prevalence of deep vein thrombosis are the critical factors attributed to the Asia Pacific DVT preventive pump market expansion.

Cardiovascular diseases (CVDs) are one of the leading causes of death APAC. In APAC, approximately three-quarters of total deaths from CVD occur in low- and middle-income countries. In such countries, people suffer from noncommunicable diseases such as CVDs as they have minimal access to effective and equitable health services. Moreover, cardiac patients have a significantly higher risk of triggering heart diseases and stroke than the general population, which can lead to the development of deep vein thrombosis (DVT). Further, the incidence of heart failure and atrial fibrillation is twice as in patients with coronary artery disease, which, in turn, contributes to the prevalence of DVT. Stroke remains an immense concern for public health, regardless of advances in understanding several factors regarding the disease, such as epidemiology, quality of life, and pathophysiology. According to the Indian Stroke Association, ~1.8 million people in India suffer a stroke yearly, and only early treatment can reduce the morbidity and mortality rates. Further, the growing incidence of stroke can lead to high risk for the population, but stroke treatment and rehabilitation are still underdeveloped in the country. Therefore, the rising cases of cardiac disorders and stroke across the APAC are increasing the prevalence of DVT, which is driving the growth of the DVT preventive pumps market. This is expected to drive the Asia Pacific DVT preventive pump market during the forecast period.

On the contrary, want of skilled professionals, side effects associated with pumps, and availability of alternatives hurdles the growth of Asia Pacific DVT preventive pump market. 

Based on type, the Asia Pacific DVT preventive pump market is bifurcated into lower extremity and upper extremity. The lower extremity segment held 67.6% of the Asia Pacific DVT preventive pump market share in 2022, amassing US$ 53.82 million. It is projected to garner US$ 74.38 million by 2028 to expand at 5.5% CAGR during 2022–2028.

Based on end user, the Asia Pacific DVT preventive pump market is categorized into hospitals and clinics, surgical centres, and others. The hospitals and clinics segment held 40.8% of the Asia Pacific DVT preventive pump market share in 2022, amassing US$ 32.50 million. It is projected to garner US$ 45.55 million by 2028 to expand at 5.8% CAGR during 2022–2028.

Based on country, the Asia Pacific DVT preventive pump market has been categorized into the China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 28.9% of the Asia Pacific DVT preventive pump market share in 2022. It was assessed at US$ 23.04 million in 2022 and is likely to hit US$ 32.09 million by 2028, exhibiting a CAGR of 5.7% during the forecast period.            

Key players dominating the Asia Pacific DVT preventive pump market are Devo Medical Products Inc.; Breg Inc.; Cardinal Health Inc.; Arjo AB; Mego Afek Ltd.; DJO LLC; Zimmer Biomet Holdings Inc.; and Medcaptain Medical Technologies Co Ltd among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com